Central sensitisation and cutaneous allodynia in migraine: implications for treatment.

CNS Drugs. 2004;18(6):337-42.
Links
Comment in:
Eur J Neurol. 2006 May;13(5):552.
Central sensitisation and cutaneous allodynia in migraine: implications for treatment.
Landy S, Rice K, Lobo B.
Wesley Headache Clinic and University of Tennessee Medical School, Memphis, Tennessee, USA. wesleyhead@aol.com
Cutaneous allodynia, pain resulting from application of a non-noxious stimulus to normal skin, is a recently described symptom of migraine, with a potential role in directing optimal treatment for migraine attacks. Manifestations of cutaneous allodynia include discomfort when combing the hair, shaving, and wearing glasses, contact lenses, earrings or tight clothing.The exact mechanism by which a migraine attack is triggered is not known, but it has been theorised that, in some patients, once the attack has begun, central neurons can propagate information about the pain process without the need for further external stimuli. This process is termed central sensitisation. The trigeminal nerves, which innervate intracranial and extracranial tissues, account for head pain and other symptoms in migraine. The first-order neurons in the trigeminal ganglion receive input from the dural blood vessels, which is transmitted to second-order neurons in the trigeminal brain stem nuclear complex and is finally sent to the third-order neurons in the thalamus. Studies in humans and animals have shown that migraine pain progresses along this neural pathway, with throbbing head pain occurring early in the attack (sensitisation of first-order neurons), followed by central sensitisation and cutaneous allodynia within the referred pain area (second-order) and finally extracephalic allodynia (third-order). The data also indicate that once central sensitisation is established in the second- and third-order neurons, migraine treatment designed to prevent the initiation of central sensitisation can lessen the pain to some extent but cannot reverse it. Thus, treatment affecting the initiation of central sensitisation should be administered immediately after the onset of migraine pain to prevent intracranial hypersensitivity and the establishment of allodynia.The serotonin 5-HT(1B/1D) agonist anti-migraine agents (the 'triptans') block meningeal nociceptor transmission at presynaptic sites in the dorsal horn. Studies have shown that triptan therapy can abort pain prior to the development of central sensitisation, but not after allodynia has been established. Therefore, in the subset of patients who report symptoms of cutaneous allodynia with migraine attacks, early initiation of triptan therapy is currently the best intervention to achieve rapid, complete and sustained pain relief.
PMID: 15089101 [PubMed - indexed for MEDLINE]
Related articles
The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine.
Brain. 2000 Aug; 123 ( Pt 8):1703-9.
[Brain. 2000]
Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization.
Ann Neurol. 2004 Jan; 55(1):27-36.
[Ann Neurol. 2004]
ReviewEffects of sensitization of trigeminovascular neurons to triptan therapy during migraine.
Rev Neurol (Paris). 2005 Jul; 161(6-7):658-60.
[Rev Neurol (Paris). 2005]
Defeating migraine pain with triptans: a race against the development of cutaneous allodynia.
Ann Neurol. 2004 Jan; 55(1):19-26.
[Ann Neurol. 2004]
ReviewCutaneous allodynia and migraine: another view.
Curr Pain Headache Rep. 2006 Jun; 10(3):231-8.
[Curr Pain Headache Rep. 2006]
» See reviews... » See all...
Cited by 1 PubMed Central article
Serotonin as a Modulator of Glutamate- and GABA-Mediated Neurotransmission: Implications in Physiological Functions and in Pathology.
Ciranna L. Curr Neuropharmacol. 2006 Apr; 4(2):101-14.
[Curr Neuropharmacol. 2006]